Johnson Pharmacare (532154) Q4 16/17 earnings summary

Executive summary

• No business activity during FY17; operating revenue was nil, and administrative costs resulted in a net loss of ₹752,769.

• Working-capital scarcity constrained operations; management cited cost reductions and a search for an opportunity to resume activity.

Financial highlights

• FY17 net loss was ₹752,769, improved from ₹1,255,927 in FY16; operating revenue was nil in both periods.

• FY17 total expenses were ₹1,221,519 versus ₹1,255,926 in FY16; no exceptional or extraordinary items were recorded.

• Paid-up equity capital remained ₹500 million; reserves and surplus were ₹82.88 million at March 31, 2017.

Outlook and guidance

• Future development depends on restarting operations; management was pursuing cost reduction and seeking an appropriate opportunity to make operations active.